Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference22 articles.
1. Morphological classification of renal cancer;Störkel;World J Urol,1995
2. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015
3. Cancer Facts & Figures,2018
4. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease;Janzen;Urol Clin North Am,2003
5. Renal Mass and Localized Renal Cancer: AUA Guideline;American Urological Association (AUA),2017
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments;JCO Precision Oncology;2023-02
2. Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma;International Journal of Molecular Sciences;2022-10-20
3. The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis;Computational and Mathematical Methods in Medicine;2022-03-29
4. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis;Urologic Oncology: Seminars and Original Investigations;2021-11
5. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis;JCO Clinical Cancer Informatics;2021-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3